| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
β-lactam
Potassium clavulanate cellulose targets bacterial beta-lactamase enzymes. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly binds to the active site of many beta-lactamases. This inhibition protects co-administered beta-lactam antibiotics (e.g., amoxicillin) from degradation, restoring their antibacterial activity against beta-lactamase-producing, resistant bacteria. The cellulose carrier is inert and has no biological activity. |
|---|---|
| ln Vitro |
At 2 μg/mL, clavulanate potassium is susceptible to both β-lactamase-positive and β-lactamase-negative amoxicillin (4 μg/mL) and ticarcillin (64 μg/mL) in combination against Bacteroides spp. and Fusobacterium spp. At MIC50 values of 8 μg/mL, clavulanate potassium (16 μg/mL) inhibits B. intermedius, B. bivius, B. disiens, B. oris, B. buccae, B. buccalis, and B. loeschei[1]. At MIC50 values of 16 μg/mL, clavulanate potassium (16 μg/mL) suppresses B. melaninogenicus, B. oralis, and F. varium[1]. The amoxicillin susceptibility rates of fusobacteria and β-lactamase-positive Bacteroides species increase from 64.2 to 88.7% and 41.3 to 90.8%, respectively, when clavulanate potassium (2 μg/mL) is added[1].
In vitro, the active component, clavulanate potassium, is an inhibitor of beta-lactamase. At a concentration of 2 microg/mL, it increases the susceptibility of beta-lactamase-positive Bacteroides species and Fusobacterium to amoxicillin (4 microg/mL) and ticarcillin (64 microg/mL). It has MIC50 values of 8-16 microg/mL against various Bacteroides strains. |
| ln Vivo |
In contrast to the control group, which had no survivors, clinvulanate potassium (125 mg; 20 d) protects 75% of mice with experimental pneumonitis[2].
In vivo, potassium clavulanate is used in combination with beta-lactam antibiotics. In an experimental mouse pneumonitis model, clavulanate potassium (125 mg) administered for 20 days protected 75% of the mice, demonstrating its ability to enhance the efficacy of antibiotics against bacterial infections when delivered in an appropriate formulation. |
| Enzyme Assay |
Potassium clavulanate cellulose is a mixture and is not used in a cell-free enzyme binding assay. However, a standard beta-lactamase inhibition assay can be performed. A bacterial beta-lactamase enzyme is incubated with a chromogenic cephalosporin substrate (e.g., nitrocefin) in the presence of potassium clavulanate cellulose. The decrease in absorbance (a measure of substrate hydrolysis) is monitored to determine the IC50.
|
| Cell Assay |
Potassium clavulanate cellulose is not used in a typical cell-based assay. However, the active component can be used in antibacterial susceptibility testing. Bacteria are cultured in Mueller-Hinton broth and treated with a beta-lactam antibiotic in the presence or absence of potassium clavulanate. The minimum inhibitory concentration (MIC) of the antibiotic is determined, and the reduction in MIC indicates synergy.
|
| Animal Protocol |
An in vivo protocol for potassium clavulanate cellulose involves a murine infection model. Female BALB/c mice are infected intranasally with a lethal dose of beta-lactamase-producing bacteria. Mice are then treated orally or intraperitoneally with amoxicillin combined with potassium clavulanate cellulose. Survival is monitored, and bacterial load in lung tissue is measured by CFU plating.
|
| ADME/Pharmacokinetics |
Potassium clavulanate is poorly absorbed from the gastrointestinal tract. When administered orally with amoxicillin, it reaches peak plasma concentrations in about 1 hour. Its elimination half-life is approximately 1 hour. It is primarily excreted unchanged in the urine. The cellulose matrix is designed for pharmaceutical formulation and is not expected to alter PK.
|
| Toxicity/Toxicokinetics |
Potassium clavulanate is generally well-tolerated. The most common adverse effects include gastrointestinal symptoms such as diarrhea, nausea, and vomiting. The cellulose component is considered inert and non-toxic. Hypersensitivity reactions may occur. The compound is not intended for research use beyond formulation and analytical studies.
|
| References |
|
| Additional Infomation |
Potassium clavulanate cellulose (1:1) is a pharmaceutical excipient or intermediate, not a drug. It is a mixture of potassium clavulanate and cellulose, a bacterial beta-lactamase inhibitor. It is used in the formulation of antibiotic combinations to enhance stability and efficacy. This product is for research and manufacturing use only, not for direct human administration.
|
| Molecular Formula |
C8H9NO5K.(C6H10O5)N
|
|---|---|
| Molecular Weight |
238.26 (Potassiumclavulanate)
|
| Related CAS # |
Clavulanic acid;58001-44-8;Cellulose;9004-34-6;Clavulanate potassium;61177-45-5
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~1 mg/mL H2O :< 0.1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
